News | December 01, 2008

Bracco Studies Support Products’ Clinical Safety and Efficacy

December 1, 2008 – At RSNA 2008, Bracco highlighted studies of its products that were the subject of multiple studies this past year, which reportedly demonstrated the company’s dedication to the manufacture of products that provide clinical safety and efficacy, including the following:

- The MR-ENHANCE study – a controlled multicenter double-blind randomized intraindividual crossover study design – published in the American Journal of Neuroradiology, suggests that the higher relaxivity of Bracco’s MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, may be linked to greater signal intensity, better contrast enhancement and better lesion conspicuity in MRI of the brain than gadodiamide.

- The PREDICT study (Patients with REnal impairment and DIabetes undergoing Computed Tomography), a prospective, randomized, double-blind comparison published in the American Journal of Roentgenology, reinforces the results of earlier published studies, IMPACT and CARE , in that it also failed to find a statistically significant difference in contrast-induced nephropathy (CIN) rates between iopamidol 370 mgl/mL (Isovue-370) and iodixanol 320 mgl/mL when administered in patients who are at high risk for a decline in renal function following the administration of intravascular contrast media.

- The ACRIN CT Colonography study published in The New England Journal of Medicine showcases the results from the largest multicenter trial on the efficacy of CT Colonography (CTC), also known as VC. With the use of Bracco’s PROTOCO2L, an automated carbon dioxide insufflation system for VC, and Tagitol V (barium sulfate suspension 40% w/v, 30% w/w) Bracco’s fecal tagging agent, researchers were able to demonstrate comparable accuracy for VC and standard colonoscopy. PROTOCO2L and Tagitol V were established as ACRIN clinical standards for use in VC.

- The Diagnostic Performance of PET Myocardial Perfusion Imaging study, a meta-analysis – published in Academic Radiology, provides a combined evaluation of numerous published studies in cardiac positron emission tomography (PET) MPI, confirming its excellent sensitivity and specificity in the diagnosis of coronary artery disease.

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...